Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | TM and Singtel's Nxera break ground for sustainable, hyper-connected data centre campus in Johor | 2 | TechNode | ||
09.07. | Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results | 1 | GlobeNewswire (USA) | ||
27.06. | Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone | 264 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd ("Nxera"; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with... ► Artikel lesen | |
20.06. | Iskandar Investment Berhad partners TM-Nxera to drive digital transformation in Iskandar Puteri | 1 | TechNode | ||
19.06. | Singtel's Nxera partners with Telekom Malaysia for Johor data center | 2 | DatacenterDynamics | ||
19.06. | Iskandar Investment partners TM-Nxera to develop RM9 bil AI-ready digital infrastructure in Iskandar Puteri | 1 | The Edge Markets | ||
19.06. | Kenanga upbeat on TM's Nxera JV | 1 | The Edge Markets | ||
19.06. | TM and Singtel's Nxera form joint venture to develop next-generation data centers in Malaysia | 2 | TechNode | ||
19.06. | TM and Nxera team up to build data centres in Malaysia | 1 | Developing Telecoms | ||
19.06. | Singtel's Nxera and Malaysia's TM partner for data centre development | 3 | Singapore Business Review | ||
18.06. | Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023 | 1 | GlobeNewswire (USA) | ||
17.06. | NeutraDC Nxera Batam starts work on AI hyperscale data centre | - | Developing Telecoms | ||
30.05. | Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area | 3 | GlobeNewswire (USA) | ||
30.05. | Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals | 148 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 30 May 2024 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals... ► Artikel lesen | |
09.05. | Sosei Group reports Q1 results | 1 | Seeking Alpha | ||
09.05. | Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults | 170 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 9 May 2024 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. ("Neurocrine"; Nasdaq: NBIX), a leading neuroscience-focused... ► Artikel lesen | |
09.05. | Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024 | 128 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 9 May 2024 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter... ► Artikel lesen | |
17.04. | Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years' RSU Plan | 1 | GlobeNewswire (USA) | ||
16.04. | Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 | 142 | GlobeNewswire (Europe) | NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine BiosciencesSuccessful completion... ► Artikel lesen | |
15.04. | Nxera and Handok partner for PIVLAZ supply in South Korea | 1 | Pharmaceutical Technology |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 28,375 | +0,11 % | Pfizer Aktie: Prognosen für Q2 2024 | Die Pfizer-Aktie steht vor einer herausfordernden Periode, da Analysten für das zweite Quartal 2024 einen Gewinnrückgang bei steigendem Umsatz erwarten. Prognosen deuten auf einen Quartalsgewinn von... ► Artikel lesen | |
NOVARTIS | 101,69 | +0,36 % | Novartis Aktie: Kursrückgang nach Analystenabstufung und IT-Störungen | Der Schweizer Pharmariese Novartis verzeichnete am Freitag einen Kursrückgang an der Börse in Zürich. Die Aktie des Unternehmens gab um 0,8 Prozent nach und notierte bei 94,33 CHF. Dieser Rückgang folgte... ► Artikel lesen | |
GILEAD SCIENCES | 70,88 | -0,08 % | Gilead's Twice-yearly Injection Offers 100% Protection Against HIV In Women: Study | FOSTER CITY (dpa-AFX) - In a recent study conducted by Gilead Sciences, Inc. (GILD) and published in the New England Journal of Medicine, it was revealed that a biannual injection of lenacapavir... ► Artikel lesen | |
SANOFI | 96,39 | +0,19 % | Sanofi SA-Aktie: Kurs klettert leicht (93,32 €) | An der Börse liegt die Sanofi SA-Aktie derzeit im Plus. Der jüngste Kurs betrug 93,32 Euro. Am Aktienmarkt hat sich heute die Sanofi SA-Aktie zwischenzeitlich um 0,45 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
ABBVIE | 170,58 | +0,01 % | European Commission Approves AbbVie's Skyrizi To Treat Ulcerative Colitis | WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) on Friday said the European Commission has approved Skyrizi for the treatment of adults with ulcerative colitis.Ulcerative colitis is a type of inflammatory... ► Artikel lesen | |
ROCHE | 298,30 | +2,35 % | DEUTSCHE BANK RESEARCH stuft ROCHE HOLDINGS AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Roche vor Halbjahreszahlen auf "Hold" mit einem Kursziel von 215 Franken belassen. Bei der Zahlenvorlage dürfte der Pharmakonzern... ► Artikel lesen | |
ABBOTT LABORATORIES | 97,17 | +0,25 % | Abbott must pay $95 million in premature infant formula trial, jury finds | ||
HAEMATO | 15,650 | -0,32 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 17.04.2024 | The following instruments on XETRA do have their last trading day on 17.04.2024Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 17.04.2024ISIN NameDE000LB32W75 LBBW FZA 22/24DE000DW6C4A6... ► Artikel lesen | |
INCYTE | 63,54 | +0,54 % | Analyst Ratings For Incyte | ||
EDWARDS LIFESCIENCES | 57,55 | +0,17 % | EQS-News: Andera Partners' Portfoliounternehmen JenaValve von Edwards Lifesciences übernommen | EQS-News: Andera Partners
/ Schlagwort(e): Firmenübernahme/Private Equity
Andera Partners' Portfoliounternehmen JenaValve von Edwards Lifesciences übernommen
25.07.2024... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,002 | +100,00 % | WPD Pharmaceuticals Inc: WPD to settle debt with shares | ||
HALEON | 4,234 | +0,88 % | ANALYSE: Bernstein wird optimistischer für Konsumgüter - Henkel hochgestuft | NEW YORK (dpa-AFX) - Nach Einschätzung des US-Analysehauses Bernstein Research ist es an der Zeit, den europäischen Konsumgütersektor positiver zu beurteilen. Die Bewertung mache es schwierig, bei... ► Artikel lesen | |
BIONANO GENOMICS | 0,623 | +3,62 % | Bionano Genomics: Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research | Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA software to Revvity's next generation sequencing... ► Artikel lesen | |
GRIFOLS | 9,216 | +0,94 % | XFRA OZTA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
TONIX PHARMACEUTICALS | 0,554 | -4,40 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya for Fibromyalgia | Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need Fast Track designation for Tonmya recognizes fibromyalgia as a serious... ► Artikel lesen |